Biomedica Research Group | Santiago, Chile
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
15,500 participants in 2 patient groups
Loading...
Central trial contact
Study Contact
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal